普洛药业(000739.SZ)：甲苯磺酸多纳非尼获得化学原料药上市申请批准

智通财经2025-06-30

智通财经APP讯，普洛药业(000739.SZ)发布公告，近日，公司控股子公司浙江普洛康裕制药有限公司收到国家药品监督管理局签发的甲苯磺酸多纳非尼《化学原料药上市申请批准通知书》。甲苯磺酸多纳非尼片(商品名：泽普生/Zepsun)是药监局批准上市的Ⅰ类创新药，上市许可持有人为公司战略合作伙伴苏州泽璟生物制药股份有限公司(以下简称“泽璟制药”);用于治疗既往未接受过全身系统性治疗的不可切除肝细胞癌，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2547063162?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-30 16:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547063162","market":"fut","top_or_hot":-1,"title":"普洛药业(000739.SZ)：甲苯磺酸多纳非尼获得化学原料药上市申请批准","media":"智通财经","content":"<div>\n<p>智通财经APP讯，普洛药业(000739.SZ)发布公告，近日，公司控股子公司浙江普洛康裕制药有限公司收到国家药品监督管理局签发的甲苯磺酸多纳非尼《化学原料药上市申请批准通知书》。甲苯磺酸多纳非尼片(商品名：泽普生/Zepsun)是药监局批准上市的Ⅰ类创新药，上市许可持有人为公司战略合作伙伴苏州泽璟生物制药股份有限公司(以下简称“泽璟制药”);用于治疗既往未接受过全身系统性治疗的不可切除肝细胞癌，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1311696.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>普洛药业(000739.SZ)：甲苯磺酸多纳非尼获得化学原料药上市申请批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n普洛药业(000739.SZ)：甲苯磺酸多纳非尼获得化学原料药上市申请批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-30 16:20 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1311696.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，普洛药业(000739.SZ)发布公告，近日，公司控股子公司浙江普洛康裕制药有限公司收到国家药品监督管理局签发的甲苯磺酸多纳非尼《化学原料药上市申请批准通知书》。甲苯磺酸多纳非尼片(商品名：泽普生/Zepsun)是药监局批准上市的Ⅰ类创新药，上市许可持有人为公司战略合作伙伴苏州泽璟生物制药股份有限公司(以下简称“泽璟制药”);用于治疗既往未接受过全身系统性治疗的不可切除肝细胞癌，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1311696.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1311696.html","article_id":"2547063162","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547063162","pubTimestamp":1751271630,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，普洛药业 发布公告，近日，公司控股子公司浙江普洛康裕制药有限公司收到国家药品监督管理局签发的甲苯磺酸多纳非尼《化学原料药上市申请批准通知书》。公司已与泽璟制药签订了研发及生产服务合同，本次获批上市的甲苯磺酸多纳非尼原料药所有权归泽璟制药所有，公司不享有其所有权，仅为其原料药生产供应商。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0188":"融资融券","BK0239":"医药制造","BK0060":"抗癌","000739":"普洛药业"},"translate_title":"Puluo Pharmaceutical (000739. SZ): Donafenib tosylate obtained approval for the marketing application of chemical raw materials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000739":1},"content_text":"智通财经APP讯，普洛药业(000739.SZ)发布公告，近日，公司控股子公司浙江普洛康裕制药有限公司收到国家药品监督管理局签发的甲苯磺酸多纳非尼《化学原料药上市申请批准通知书》。甲苯磺酸多纳非尼片(商品名：泽普生/Zepsun)是药监局批准上市的Ⅰ类创新药，上市许可持有人为公司战略合作伙伴苏州泽璟生物制药股份有限公司(以下简称“泽璟制药”);用于治疗既往未接受过全身系统性治疗的不可切除肝细胞癌，以及进展性、局部晚期或转移性放射性碘难治性分化型甲状腺癌。公司已与泽璟制药签订了研发及生产服务合同，本次获批上市的甲苯磺酸多纳非尼原料药所有权归泽璟制药所有，公司不享有其所有权，仅为其原料药生产供应商。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2547063162","isCrawlerRequest":true}